About this trial
Borderline personality disorder (BPD) is a common mental disorder in adolescents with significant individual and societal repercussions, characterized over the long term by emotional hyperresponsiveness, relational instability, identity disturbances and self-aggressive behavior. The etiology of BPD is multifactorial and involves exposure to traumatic life events, which are present in the majority of cases. This explains the very common co-morbidity between BPD and post-traumatic stress disorder (PTSD), which involves emotionally painful memory relapses of one or more traumatic events, associated with an emotional trauma avoidance syndrome (s). ) and hypervigilance. Brain imaging studies in adolescents with BPD have shown decreases in the volume of gray matter within the frontolimbic network, as well as a decrease in frontolimbic white matter bundles. These brain changes are considered to be biological markers of TPB. However, the exact same brain changes are seen in PTSD. Although it represents more than a third of adolescents hospitalized in psychiatry, neuroscientific studies of BPD in adolescence are still scarce. The expertise we have acquired in U1077 in adolescents with PTSD offers us an exceptional opportunity to characterize in BPD with and without PTSD structural anomalies, including the hippocampus, and functional at rest, never used for hour in the teenager's BPD. Beyond that, carrying out an 18-month follow-up of the patients will allow us to assess the predictive value of these anomalies on the level of general psychopathology in all the patients studied and the intensity of the symptoms of traumatic relapse in the patients with PTSD. This modeling of disorders integrating psychopathological, neuropsychological and neuroanatomical approaches will provide the clinician with new knowledge necessary for therapeutic innovation.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
female
Age between 13 and 17 years inclusive
Oral and written comprehension of the French language
Affiliation to the social security scheme
Disqualifiers
- Illiteracy / illiteracy
Sensory disorder (visual, auditory)
Severe chronic psychiatric comorbidity: autism spectrum disorder, intellectual disability, schizophrenia spectrum disorder and other psychotic disorders, bipolar disorder
Severe or current brain pathology (chronic neurological disease, encephalitis, history of severe head trauma), alertness disorder
Trial design
Parallel
Treatments tested in this trial
Brain MRI
Other interventionAnatomical MRI The anatomical data will be acquired by means of a 3T Signa Premier General Electric Healthcare MRI, allowing the acquisition of classic anatomical sequences (T1, T2) and a high-resolution hippocampal sequence allowing to accurately apprehend its various sub-fields. (total acquisition time: 10 min). The hippocampal volume, the orbital-frontal cortex and the cingulate cortex will be measured by voxel-based morphometry (VBM; Ashburner \& Friston, 2000\]) using the SPM software (Statistical Parametric Mapping; Friston et al., 2006). The voxel-by-voxel morphometric analysis of T1 MRI images makes it possible to classify and segment the different brain tissues (gray matter versus white matter) and to analyze the focal differences in volume within these tissues between the different groups.
Treatment groups
Trial outcomes
Primary outcomes
Hippocampal volume
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University Hospital, Caen
Lead sponsor
CHU de Rouen - Accueil
Collaborator
Centre Hospitalier Universitaire de Caen
Collaborator
Université de Caen Normandie
Collaborator
Centre Hospitalier du Rouvray
Collaborator
Institut National de la Santé Et de la Recherche Médicale, France
Collaborator
Groupe Hospitalier du Havre
Collaborator